Rothschild Redburn raised Abbott Laboratories stock target from USD 119.00 to USD 127.00

Published on 10/21/2026 at 10:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales rose 13.00 percent to USD 12.59 billion. Abbott Laboratories stock is EUR 90.67 on October 21, 2026, 1.27 percent below Xetra's EUR 91.84 close.

Analyst view and earnings setup

Rothschild Redburn raised its Abbott target from USD 119.00 to USD 127.00 on October 2, 2026.
Second-quarter sales reached USD 12.59 billion, up 13.00 percent year over year.
Abbott Laboratories stock trades at EUR 90.67 at 10:52 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.27 percent below the Xetra close of October 20, 2026.

NYSE-Börsensaal Healthcare-Charts Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 NYSE-Börsensaal Editorial mit Healthcare-Aktiencharts Händlern und digitalen Kurstafeln Bildschirmen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) stock was trading at EUR 90.67 at Lang & Schwarz on October 21, 2026 at 10:52 a.m. CEST, down 1.27 percent versus the Xetra close of October 20, 2026 (EUR 91.84). On October 2, 2026, Rothschild Redburn raised its rating from Neutral to Buy and lifted its target from USD 119.00 to USD 127.00, as reported by Investing.com.

Three milestones shape the setup

On June 12, 2026, Abbott declared a quarterly dividend of USD 0.63 per share, payable on August 17, 2026, according to a release carried by Trivano. On July 16, 2026, the company reported second-quarter sales of USD 12.593 billion, up 13.00 percent from the year-earlier quarter, and adjusted diluted earnings per share of USD 1.31.

On October 2, 2026, Rothschild Redburn's target change completed the recent sequence, with the analyst citing projected fiscal-year 2026 organic growth of 10.60 percent in Medical Devices. The same report identified Abbott's diabetes technology business as a growth area, with projected fiscal-year 2026 growth of 11.70 percent.

What does the earnings bar require?

Abbott's second-quarter numbers set a measurable comparison. The company reaffirmed full-year 2026 comparable sales growth guidance of 6.50 percent to 7.50 percent and raised adjusted diluted earnings-per-share guidance to USD 5.45-5.60 from USD 5.38-5.58, according to the July 16 release carried by Trivano. That combination leaves the third-quarter report to test whether device growth can offset pressure in Nutrition, where second-quarter sales fell 3.10 percent.

Next dates for Abbott

MarketBeat lists October 21, 2026, as the date for Abbott's third-quarter results before the U.S. open and 9:00 a.m. ET for the earnings call. Its consensus calls for USD 12.99 billion in revenue and USD 1.42 in earnings per share for the quarter, compared with USD 11.37 billion and USD 1.30 in the year-earlier quarter.

Stock trades below the Xetra close

The euro quotation places the stock below the prior Xetra session's close while the upcoming report supplies the immediate test for the guidance range. At Lang & Schwarz, Abbott Laboratories was trading at EUR 90.67 on October 21, 2026 at 10:52 a.m. CEST, 1.27 percent below the Xetra close of October 20, 2026 at EUR 91.84. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.